edoc

Risk and management of patients with mastocytosis and MCAS in the SARS-CoV-2 (COVID-19) pandemic: expert opinions

Valent, Peter and Akin, Cem and Bonadonna, Patrizia and Brockow, Knut and Niedoszytko, Marek and Nedoszytko, Boguslaw and Butterfield, Joseph H. and Alvarez-Twose, Ivan and Sotlar, Karl and Schwaab, Juliana and Jawhar, Mohamad and Reiter, Andreas and Castells, Mariana and Sperr, Wolfgang R. and Kluin-Nelemans, Hanneke C. and Hermine, Olivier and Gotlib, Jason and Zanotti, Roberta and Broesby-Olsen, Sigurd and Horny, Hans-Peter and Triggiani, Massimo and Siebenhaar, Frank and Orfao, Alberto and Metcalfe, Dean D. and Arock, Michel and Hartmann, Karin. (2020) Risk and management of patients with mastocytosis and MCAS in the SARS-CoV-2 (COVID-19) pandemic: expert opinions. The Journal of Allergy and Clinical Immunology, 146 (2). pp. 300-306.

Full text not available from this repository.

Official URL: https://edoc.unibas.ch/77501/

Downloads: Statistics Overview

Abstract

The COVID-19 (SARS-CoV-2) pandemic has massively distorted our health care systems and caused catastrophic consequences in our affected communities. The number of victims continues to increase and patients at risk can only be protected to a degree, since the virulent state may be asymptomatic. Risk factors concerning COVID-19-induced morbidity and mortality include advanced age, an impaired immune system, cardiovascular or pulmonary diseases, obesity, diabetes mellitus, and cancer treated with chemotherapy. Here within, we discuss the risk and impact of COVID-19 in patients with mastocytosis and mast cell activation syndromes. As no published data are yet available, expert opinions are, by necessity, based on case experience and reports from patients. Whereas the overall risk to acquire the SARS-CoV-2 virus may not be elevated in mast cell disease, certain conditions may increase the risk of infected patients to develop severe COVID-19. These factors include certain co-morbidities, mast cell activation-related events affecting the cardiovascular or bronchopulmonary system and chemotherapy or immunosuppressive drugs. Therefore, such treatments should be carefully evaluated on a case-by-case basis during a COVID-19 infection. By contrast, other therapies, such as anti-mediator-type drugs, venom immunotherapy, or vitamin D, should be continued. Overall, patients with mast cell disorders should follow the general and local guidelines in the COVID-19 pandemic and advice from their medical provider.
Faculties and Departments:03 Faculty of Medicine > Bereich Spezialf├Ącher (Klinik) > Dermatologie USB > Allergologie (Hartmann)
03 Faculty of Medicine > Departement Klinische Forschung > Bereich Spezialf├Ącher (Klinik) > Dermatologie USB > Allergologie (Hartmann)
03 Faculty of Medicine > Departement Biomedizin > Department of Biomedicine, University Hospital Basel > Allergy and Immunity (Hartmann)
UniBasel Contributors:Hartmann, Karin
Item Type:Article, refereed
Article Subtype:Research Article
ISSN:0091-6749
Note:Publication type according to Uni Basel Research Database: Journal article
Identification Number:
Last Modified:17 Dec 2021 17:23
Deposited On:17 Dec 2021 17:23

Repository Staff Only: item control page